166 related articles for article (PubMed ID: 3873988)
1. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
Kataoka T; Oh-hashi F
Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
[TBL] [Abstract][Full Text] [Related]
2. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
Kataoka T; Akahori Y; Sakurai Y
Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
[TBL] [Abstract][Full Text] [Related]
3. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
[TBL] [Abstract][Full Text] [Related]
4. Suppressor macrophages in tumor-bearing mice and their selective inhibition by 6-mercaptopurine.
Kataoka T; Oh-hashi F
Cancer Res; 1985 May; 45(5):2139-44. PubMed ID: 3157443
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin C-augmented production of I-A antigen-positive macrophages in tumor vaccine-primed mice.
Kataoka T; Yamamoto T; Honjo K; Murayama T
Jpn J Cancer Res; 1986 Mar; 77(3):305-11. PubMed ID: 3009373
[TBL] [Abstract][Full Text] [Related]
6. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
[TBL] [Abstract][Full Text] [Related]
7. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
Miura T; Maekawa T; Kurashige S; Mitsuhashi S
Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
[TBL] [Abstract][Full Text] [Related]
8. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.
Kataoka T; Oh-Hashi F; Sakurai Y
Gan; 1982 Apr; 73(2):193-205. PubMed ID: 6811360
[TBL] [Abstract][Full Text] [Related]
10. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
[TBL] [Abstract][Full Text] [Related]
11. Studies on the properties of a streptococcal preparation OK-432 (NSC-B116209) as an immunopotentiator. I. Activation of serum complement components and peritoneal exudate cells by group A streptococcus.
Sakai S; Ryoyama K; Koshimura S; Migita S
Jpn J Exp Med; 1976 Apr; 46(2):123-33. PubMed ID: 778447
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant activity of the cell wall of Bifidobacterium infantis for in vivo immune responses in mice.
Sekine K; Watanabe-Sekine E; Toida T; Kasashima T; Kataoka T; Hashimoto Y
Immunopharmacol Immunotoxicol; 1994 Nov; 16(4):589-609. PubMed ID: 7876463
[TBL] [Abstract][Full Text] [Related]
13. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
Nagase F; Ueda K; Kawashima K; Jamshedur Rahman SM; Isobe K; Yoshida T; Hasegawa Y; Ando K; Iwamoto T; Nagura E
J Immunol; 1987 Apr; 138(7):2359-65. PubMed ID: 2951438
[TBL] [Abstract][Full Text] [Related]
14. Immunoprophylactic and immunotherapeutic response by concanavalin A-bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors.
Kataoka T; Ogihara K; Sakurai Y
Cancer Res; 1980 Oct; 40(10):3839-45. PubMed ID: 6449286
[TBL] [Abstract][Full Text] [Related]
15. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
Kataoka T; Oh-hashi F; Sakurai Y
Cancer Res; 1979 Jul; 39(7 Pt 1):2807-10. PubMed ID: 445486
[TBL] [Abstract][Full Text] [Related]
17. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro.
Fuji H; Mihich E; Pressman D
J Immunol; 1977 Sep; 119(3):983-6. PubMed ID: 330761
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
